A PK Comparability Study of Two Different Amlitelimab Drug Products in Healthy Participants

Healthy Volunteers Clinical Trial

Official title:

A 2-part, Open Label, Phase 1 Study to Investigate the Pharmacokinetics, Safety and Tolerability of Two Different Amlitelimab Drug Products After Administration of a Single Subcutaneous Dose in Healthy Adult Participants

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05796479
• Other study ID #: PKM17597
• Status: Completed
• Phase: Phase 1
• Start date: April 28, 2022
• Est. completion date: May 22, 2023

Study information

• Verified date: May 2023
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a 2-part, Phase 1 study, with 1 arm in Part 1 and a randomized parallel design in Part 2. The purpose of this study is to evaluate the comparability of pharmacokinetics, safety and tolerability of two different amlitelimab drug products (DPs) after administration of a single subcutaneus (SC) dose in healthy adult participants.

Study details include:

The study duration for a participant will be approximately 17 weeks. The study includes a screening period of up to 28 days, a 4-day institutionalization period, and a follow up period for approximately 89 days (9 visits).

Description:

The study duration for a participant will be approximately 17 weeks

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: May 22, 2023
• Est. primary completion date: May 22, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent.

• Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, ECG, and laboratory tests

• Body weight within 55 to 100 kg and body mass index (BMI) within the range 18-30 kg/m2 (inclusive)

• Male or female of childbearing potential are required to either practice true abstinence consistent with their preferred and usual lifestyle or use highly effective contraceptive methods for the entire duration of the treatment until 4 months after the investigational medicinal product (IMP) dosing.

Exclusion Criteria:

• Any history or presence of clinically relevant immunologic, cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, or infectious disease, or signs of acute illness, unless the investigator considers an abnormality to be not clinically significant.

• Participants with a history of helminthic infection or invasive opportunistic infections such as histoplasmosis, listeriosis, coccidioidomycosis, candidiasis, Pneumocystis jirovecii, aspergillosis, irrespective of resolution.

• Serious infections requiring hospitalization within 30 days prior to screening or any active infection requiring treatment during screening.

• Current or past diagnosis of malignancies within the last 5 years prior to screening (except documented history of cured non-metastatic squamous or basal cell skin carcinoma or cervical carcinoma in situ).

• Presence or history of drug hypersensitivity or allergic disease diagnosed and treated by a physician.

• Evidence of active or latent tuberculosis (TB XE ' TB ' \f Abbreviation \t 'tuberculosis ' ) as documented by medical history and examination; TB testing via a positive (not indeterminate) QuantiFERON TB Gold test

• If female, pregnancy (defined as positive beta human chorionic gonadotropin [ß-HCG] test), or lactating. - Received a live (attenuated) immunization within 12 weeks prior to inclusion or non-live immunization within 4 weeks prior to inclusion.

• Any medication, with the exception of hormonal contraception, within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic half-life of the medication, whichever is longer, and any biologics (antibody or its derivatives) given within 4 months before inclusion.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Drug:
• Amlitelimab DP1
Injection solution 1 Subcutaneous
• Amlitelimab DP2
Injection solution 2 Subcutaneous

Locations

Country	Name	City	State
United States	Clinical Pharmacology of Miami-Site Number: 8400001	Hialeah	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part 1: Maximum Plasma concentration observed (Cmax )	Cmax after administration of a single SC dose of amlitelimab DP 1	From Day1 up to Day92 (end of study [EOS])
Primary	Part 1: Area under the curve from the time of dosing to the last measurable concentration (AUClast)	AUClast after administration of a single SC dose of amlitelimab DP 1	From Day1 up to Day92 (EOS)
Primary	Part 1: Area under the plasma concentration versus time curve extrapolated to infinity (AUC)	AUC after administration of a single SC dose of amlitelimab DP 1	From Day1 up to Day92 (EOS)
Primary	Part 2: Cmax of two different amlitelimab DPs (DP1 and DP2)	Cmax after administration of a single SC dose of amlitelimab DP 1 and DP2	From Day1 up to Day92 (EOS)
Primary	Part 2: AUClast of two different amlitelimab DPs (DP1 and DP2)	AUClast after administration of a single SC dose of amlitelimab DP1 and DP 2	From Day1 up to Day92 (EOS)
Primary	Part 2: AUC of two different amlitelimab DPs (DP1 and DP2)	AUC after administration of a single SC dose of amlitelimab DP1 and DP 2	From Day1 up to Day92 (EOS)
Secondary	Part 1 and Part 2: Incidence of adverse events (AE)/treatment-emergent adverse events (TEAEs)	Incidence of AEs and TEAEs after administration of amlitelimab will be reported.	From the signing of the informed consent form (ICF) up to Day92 EOS visit